Cytokinetics vs Gyre Therapeutics
CYTK and GYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYTK and GYRE compare
Gyre Therapeutics is the larger company, worth 65 times as much as Cytokinetics ($508M against $7.8M).
Gyre Therapeutics grew revenue faster over the last twelve months (13.5% versus −21.1% for Cytokinetics).
Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −23.6% compared with −1321% at Cytokinetics.
Gyre Therapeutics scores higher on the StockData Score (13 against 4 for Cytokinetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYTK | GYRE |
|---|---|---|
| Size and price | ||
| Market cap | $7.8M | $508M |
| Share price | $62.99 | $4.55 |
| Change, 1 year | 1.6% | −39.6% |
| Change, 5 years | 53.3% | −90.2% |
| Beta (5Y) | 0.82 | 2.21 |
| Employees | 673 | 618 |
| StockData Score | ||
| Total score | 4 | 13 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 4.3× |
| P/B | – | 4.7× |
| FCF yield | −7408% | −1.2% (better) |
| Fair value | – | $5.74 |
| Margin of safety | – | 20.6% |
| Growth | ||
| Revenue growth (TTM) | −21.1% | 13.5% (better) |
| Revenue growth, 5Y average | 9.5% | 41.0% (better) |
| Net income growth (TTM) | – | −559% |
| Profitability | ||
| Gross margin | – | 94.3% |
| Operating margin | −1046% | −14.0% (better) |
| Net margin | −1321% | −23.6% (better) |
| FCF margin | −858% | −5.1% (better) |
| Return on equity | – | −28.2% |
| Return on invested capital | – | −29.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 6.66 (better) | 4.26 |
| Altman Z-score | −3.37 | 8.79 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 115% | 7.8% |
| Held by insiders | 0.68% | 93.8% |
| Insider net buying, 12 months | −$50.6M | −$953K (better) |
| Short interest, % of float | 14.0% | 27.7% |
Go deeper
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
- GYRE stock overview
- GYRE income statement
- GYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.